SACRAMENTO, Calif.,
May 15, 2019 /PRNewswire/ -- Dr.
Chris Yu, Chief Executive Officer of
international life sciences corporation, Anpac Bio-Medical Science
Company (Anpac Bio), announced today that the company's
United States subsidiary, Anpac
Technology USA, successfully
passed the State of California
survey for Clinical Laboratory Improvement Amendments or CLIA '88
certification; and thus may now offer diagnostic services to human
subjects for clinical research in its San
Jose, California-based laboratory.
Anpac Bio's CLIA certification validates that the company's
laboratory processes are standardized to consistently meet and
exceed the Federal and Clinical Laboratory Standards Institute's
(CLSI) guidelines for accuracy, precision, and sensitivity.
Anpac Bio-Medical Science Company was founded in 2010 by a team
of medical, biomedical, nanotechnology scientists, and engineers,
to develop and launch an innovative, early cancer screening and
detection liquid biopsy technology known as, "Cancer
Differentiation Analysis" (CDA). Comprehensive research validity
data from 100,000+ cases processed, demonstrate CDA diagnostics
consistently detects over 20 different cancers - usually at the
diseases' earliest stages – from simple, standard blood tests. And
it does so without harmful patient side effects; generating
far fewer "false positives"; and at a cost, substantially lower
than traditional testing (such as imaging). Anpac Bio has
filed over 200 CDA-related patent applications worldwide; with over
100 issued by 20 countries (to date).
Anpac Bio has presented CDA research results before key medical
bodies such as American Society of Clinical Oncology; and the
American Association of Cancer Research; among others. Multi-award
winning, the company has received the "Breakthrough Innovation
Award" at the World Nobel Prize Laureate Summit; named, "Most
Promising Cancer Screening Company" at the Global Precision
Medicine Industry Awards; was bestowed the international, "Big
Innovation Award" and "World Changing Ideas Award" in Health &
Wellness; and named by the United States Department of Commerce as
the national, "Minority Health Firm of the Year".
"We are pleased about the new addition of our CLIA certified
laboratory in San Jose,
California," states Yu. "Together with our multiple clinical
and research laboratories in Asia,
we are positioned very well to commercialize our CDA technology in
the United States and
globally."
For further information: AnpacBio.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anpac-bio-gains-us-clia-lab-certification-300851046.html
SOURCE Anpac Bio-Medical Science Company